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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The main objective is to assess the results at two years of supraciliary drainage devices for OAG in comparison to conventional medical,
laser, surgical treatment in terms of efficacy and safety. A secondary objective will be to examine the effects of supraciliary drainage
devices with concomitant phacoemulsification in comparison to supraciliary drainage devices alone.
B A C K G R O U N D
Description of the condition
Glaucoma is a chronic progressive optic neuropathy, affecting up
to 4% of people by the age of 80 years (Burr 2007). It is the leading
cause of irreversible blindness, affecting 60million people globally
(Quigley 2006). This figure is expected to increase to 80 million
people by 2020. Open angle glaucoma (OAG) is the commonest
type, accounting for three-quarters of cases (Quigley 2006). In
one large population cohort, one in six patients withOAGbecame
bilaterally blind (Peters 2013). The only proven way to prevent
vision loss is to reduce the pressure inside the eye (intraocular pres-
sure) over the long term (AGIS 2000; CNTG Study Group 1998;
Heijl 2002; Kass 2002). Approaches to reducing intraocular pres-
sure (IOP) include medical therapy, laser treatments, and surgery.
Commercially available eye-drop preparations have a short-lasting
effect, medical therapy requires eye-drops to be instilled one or
more times daily for life. Adherence is very poor, even if use is
monitored (Friedman 2009; Okeke 2009). Conventional surgical
techniques such as trabeculectomy are associated with significant
risks, with more than 40% of patients developing perioperative
complications (Kirwan 2013; Lichter 2001) and reoperation being
needed in 7% to 18% (Gedde 2012; Kirwan 2013). Therefore,
they are often reserved for disease that is progressing despite other
treatments (King 2013).
Description of the intervention
Recently, a number of minimally-invasive surgical techniques have
been developed with the aim of achieving long-term reduction
of IOP with a better safety profile than conventional surgery (
Francis 2011). Among them is ab interno supraciliary microstent
surgery, the Cypass (Alcon Laboratories, a division of Novartis,
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Basel, Switzerland) and the iStent Supra (Glaukos Corporation,
Laguna Hills, CA, USA) are current devices. The former is FDA
approved and also CEmarked in Europe. The latter is undergoing
a phase 3 clinical trial with a view to obtaining FDA approval, but
is CE marked in Europe.
How the intervention might work
In cases of open angle glaucoma, an increased resistance to outflow
is thought to exist not only at the level of the trabecular meshwork
but also within the ciliary body part of the uveoscleral pathway.
With the uveoscleral pathway thought to contribute up to half of
physiological aqueous outflow (Toris 1999), supraciliary micros-
tents such as the Cypass and iStent Supra have been developed
to exploit this, leading to an increase in aqueous outflow and a
reduction in intraocular pressure.
Why it is important to do this review
Consultationwith patients and healthcare professionals has identi-
fied a need for better treatments for glaucoma (James Lind Alliance
2013). Minimally-invasive glaucoma procedures carry the possi-
bility of safe and effective long-term reduction of IOP, removing
concerns about permanent vision loss due to nonadherence to eye-
drops. A single treatment may also be more acceptable to patients
than daily and indefinite self-administration of eye-drops.
The evidence base intended to support the use of supraciliary mi-
crostents in practice continues to grow. Randomised controlled
clinical studies to assess the safety and efficacy of the Cypass and
iStent Supra alone have recruited in excess of 1000 patients. How-
ever, what is less clear is where this evidence lies in the current
landscape of existing interventional options to manage open angle
glaucoma, presently including medical, laser, trabeculectomy and
other minimally-invasive glaucoma procedures. Since phacoemul-
sification itself reduces IOP (Mansberger 2012), we will specifi-
cally examine the evidence for the efficacy of supraciliary drainage
devices when combined with phacoemulsification in comparison
to phacoemulsification alone.
With both the Cypass and iStent Supra devices holding a CEmark
for use in Europe and the Cypass already FDA approved, the user
availability of such supraciliary microstents is expected to grow,
increasing the importance of a review that will critically evaluate
the current evidence relating to this group of devices.
This Cochrane review will be conducted in parallel with other
reviews currently undertaken by the Cochrane Eyes and Vision
MIGS Consortium, which includes minimally-invasive glaucoma
surgery (MIGS) techniques and devices such as the Trabectome
(NeoMedix, Tustin, California) (Hu 2016), Hydrus Schlemm’s
canal Microstent (Ivantis Inc., Irvine, California) (Otarola 2017),
endoscopic cytophotocoagulation (ECP) (EndoOptiks,Waltham,
Massachusetts) (Tóth 2017), XEN Glaucoma Implant (AqueSys
Implant, Aliso Viejo, California) (King 2017) and IStent or IStent
inject (Glaukos Corporation, Laguna Hills, California) (Le 2017).
O B J E C T I V E S
The main objective is to assess the results at two years of supra-
ciliary drainage devices for OAG in comparison to conventional
medical, laser, surgical treatment in terms of efficacy and safety. A
secondary objective will be to examine the effects of supraciliary
drainage devices with concomitant phacoemulsification in com-
parison to supraciliary drainage devices alone.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include randomised controlled trials (RCTs) only. We will
include reports of RCTs prepared in any language irrespective of
their publication status.
Types of participants
Participants will have OAG of any type, including primary and
secondary OAG.Closed angle glaucoma will be excluded. As there
are no universally-accepted criteria by which glaucoma may be de-
fined, we will permit studies to use their own definitions of glau-
coma (provided these are clearly stated). In addition, participants
with ocular hypertension, normal tension glaucoma, or possible
glaucoma (suspects for glaucoma) will be included. We will not
apply any restrictions regarding location, setting, or demographic
factors.
Types of interventions
The interventionwill be ab interno supraciliarymicrostent surgery
with the Cypass (Alcon Laboratories, a division of Novartis, Basel,
Switzerland), iStent Supra (Glaukos Corporation, Laguna Hills,
CA, USA) or other supraciliary microstents that are identified
during this review.
We will compare supraciliary microstent surgery to:
1. laser treatment (selective laser trabeculoplasty or argon laser
trabeculoplasty);
2. other MIGS techniques;
3. conventional glaucoma surgery (trabeculectomy)
4. medical therapy; or
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5. in combination with phacoemulsification compared with
phacoemulsification alone (since phacoemulsification cataract
surgery is known to reduce IOP (Mansberger 2012)).
Types of outcome measures
We will not use the reporting of particular outcomes as a criterion
for eligibility for review. We will not exclude studies from review
solely on the grounds of an outcome of interest not being reported.
Primary outcomes
The primary outcome will be the proportion of participants who
are drop-free (not using eye-drops) at two years after randomisa-
tion.
Several different glaucoma outcome measures have been specified
as primary outcomes in other Cochrane Reviews and protocols
(Ismail 2015). A recent study classified IOP, visual field, safety,
and anatomic outcomes as being highly important to glaucoma
experts (Ismail 2016). A panel of patients from the Patient and
Public Involvement Group of the National Institute for Health
Research (NIHR) Biomedical Research Centre for Ophthalmol-
ogy identified drop-free disease control as a highly valued outcome
(unpublished). We chose a participant-centred primary outcome.
Secondary outcomes
Secondary outcomes will be:
1. Mean change in IOP, measured using Goldmann
applanation tonometry, from randomisation to two years.
2. The proportions of participants experiencing intra- and
postoperative complications from randomisation to two-year
follow-up, including but not restricted to the following:
◦ Loss of visual acuity (more than two Snellen lines or
more than 0.3 logMAR, according to the method of recording
visual acuity; or loss of light perception).
◦ Bleeding, as recorded by the investigators.
◦ Endophthalmitis, as recorded by the investigators.
◦ IOP spikes (postoperative rise in IOP, measured using
Goldmann applanation tonometry, of more than 10 mmHg
compared to the previous assessment, including during the first
postoperative month).
◦ Secondary surgery, as recorded by the investigators.
3. Change in health-related quality of life measure, from
randomisation to two-year follow-up.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search
the following electronic databases for randomised controlled trials
and controlled clinical trials. There will be no language or publi-
cation year restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (which contains the Cochrane Eyes and Vision
Trials Register) in the Cochrane Library (latest issue) (Appendix
1);
• MEDLINE Ovid (1946 to present) (Appendix 2);
• Embase Ovid (1980 to present) (Appendix 3);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch
(Appendix 4);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 5);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp)
(Appendix 6).
Searching other resources
We will search the reference lists of included studies for other
possible studies and will contact any individuals or organisations
who, we believe, may have conducted or be conducting relevant
RCTs. We will also search the website of themanufacturer (Ivantis
Inc., Irvine, California; www.ivantisinc.com) for any information
on forthcoming trials.
Data collection and analysis
Selection of studies
Two review authors working independently will screen titles and
abstracts of all articles identified by the search using web-based on-
line review management software (Covidence 2015). If abstracts
are not available, we will screen full-text articles. Two review au-
thors will independently assess full-text reports of all potentially
eligible studies. If there is disagreement regarding eligibility, a third
review author will arbitrate. If any full-text reports are rejected, we
will record the reasons for this.
Data extraction and management
We will extract data from reports of included studies using a data
collection form, which will be developed and piloted on the first
five studies included. Two review authors will work independently
to extract study characteristics from reports of each study and enter
the data into Review Manager 5 (RevMan 5) (Review Manager
2014). If there is disagreement, a third independent review author
will arbitrate.
We will collect the following information on the characteristics of
included studies (Appendix 7):
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• Year of publication.
• Year of study.
• Country of study.
• Sample size.
• Participation rate.
• Method of recruitment.
• Eligibility criteria.
• Diagnostic criteria.
• Method of randomisation.
• Method of masking.
• Number of study arms.
• Types of participants.
• Types of interventions.
• Types of comparators.
• Use of phacoemulsification at the same time as the
intervention.
We will collect the following data regarding outcomes (Appendix
7):
• IOP at baseline.
• IOP at follow-up.
• Number of glaucoma medications at baseline.
• Number of glaucoma medications at follow-up.
• Intraoperative complications.
• Postoperative complications or secondary surgery.
• Duration of follow-up.
• Loss to follow-up.
• Intervals at which outcomes were assessed.
Where data on included studies are missing or unclear, we will
contact the individuals or organisations involved to obtain clari-
fication. We will collect and use the most detailed numerical data
available to facilitate analyses of included studies. We will attempt
to obtain these data from individuals or organisations in prefer-
ence to less precise methods such as extracting numeric data from
graphs. If this is necessary, two independent review authors will
extract the data and a third review author will arbitrate, in case of
disagreement.
Assessment of risk of bias in included studies
We will use the latest version of the Cochrane ’Risk of bias’ tool
as described in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) to assess the risk of bias
and assign judgements of this for included studies.
Measures of treatment effect
The primary outcome is the proportion of participants who are
drop-free two years after randomisation. We will use a risk ratio
as the treatment effect measure. In assessing this effect measure,
we will report how prescribing of IOP-lowering eye-drops was
determined during follow-up.Wewill examinewhether the people
measuring IOP and those deciding upon the prescribing of IOP-
lowering eye-drops were masked to treatment group.
We will report mean change in IOP from randomisation to two
years after randomisation. Secondary safety outcomes will be re-
ported as risk ratios. Health-related quality of life outcomes will
be reported as differences in means or risk ratios for continuous
and binary data, respectively.
Unit of analysis issues
We will assess whether included studies have included one or two
eyes from each subject and whether or not randomisation has been
conducted at the level of the participant or the eye. There is a
potential for medical treatments, such as topical beta blockers used
for one eye, to influence the outcome in the other eye (Piltz 2000).
Surgery to lower IOP in one eye may also affect the IOP of the
fellow eye (Radcliffe 2010). Therefore, we will exclude studies that
have adopted a paired design.
Dealing with missing data
We will endeavour to minimize missing outcome data by con-
tacting individuals and organisations to obtain them. If the data
are unavailable but the level of missing data in each group and
reasons for missing data in each group are similar we may simply
analyse available-case data if an intention-to-treat (ITT) analysis
has not been performed.We will report if authors have conducted
their own ITT analysis despite missing data, but we will document
whether they provide any justification for the method they have
used to deal with missing data and whether they have compared
their ITT result with an available-case result.
Assessment of heterogeneity
Wewill assess the heterogeneity between trials by careful examina-
tion of the study reports, assessing forest plots and an examination
of the I2 value. We will consider I2 values greater than 50% as
indicative of substantial heterogeneity, suggestive that meta anal-
ysis might not be wise - however, consideration will be given to
the consistency of the effect estimates. If all estimates are in the
same direction, we might meta-analyse even where heterogeneity
is evident; we will comment on the heterogeneity.
Assessment of reporting biases
We will use a funnel plot to assess the risk of publication bias if
there are more than 10 trials within our review.
Data synthesis
We will undertake a meta-analysis where data appear clinically,
methodologically, and statistically homogeneous. We will check
that participants, interventions, comparators, and outcomes are
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sufficiently similar to give a clinically meaningful result and that
our I2 result does not indicate considerable inconsistency (i.e. I
2 less than 50%). If all estimates are in the same direction, we
might meta-analyse even where heterogeneity is evident but will
comment on this.We will use a random-effects model unless there
are fewer than three eligible studies, in which case, we will use a
fixed-effect model.
Subgroup analysis and investigation of heterogeneity
We will undertake a subgroup analysis. The effect modifier to be
examined will be use of phacoemulsification as a cointervention.
Phacoemulsification has been shown to reduce IOP (Mansberger
2012). We will therefore analyse whether the effect of Hydrus
surgery differs depending on whether phacoemulsification is used
as a cointervention.
Sensitivity analysis
We will assess the impact of including studies at high risk of bias
for an outcome in one or more key domains.
Summary of findings
We will prepare tables to summarise the findings of the review,
including the assessment of the certainty of evidence for all out-
comes using the GRADE approach (GRADEpro 2014).
We will report the following outcomes in the ’Summary of find-
ings’ table and the comparison groups described under Types of
interventions: ab interno supraciliary microstent surgery com-
pared with laser treatment, other MIGS techniques, conventional
glaucoma surgery (trabeculectomy), medical therapy or in com-
bination with phacoemulsification compared with phacoemulsifi-
cation alone.
1. Proportion of participants who are drop-free (not using eye-
drops) at two years follow-up.
2. Mean change in number of IOP-lowering drops taken per
day from baseline to two years follow-up.
3. Mean change in IOP, measured using Goldmann
applanation tonometry, from baseline to two years follow-up.
4. Health-related quality of life at two years follow-up.
5. Intraoperative complications.
6. Postoperative complications, up to two years follow-up.
7. Secondary glaucoma surgery, including laser, as recorded by
the investigators of the included trials between baseline and two
years follow-up.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Glaucoma, Open-Angle] explode all trees
#2 MeSH descriptor: [Intraocular Pressure] explode all trees
#3 MeSH descriptor: [Ocular Hypertension] explode all trees
#4 OAG or POAG or IOP or OHT
#5 simple near/3 glaucoma*
#6 open near/2 angle near/2 glaucoma*
#7 chronic near/2 glaucoma*
#8 secondary near/2 glaucoma*
#9 low near/2 tension near/2 glaucoma*
#10 ow near/2 pressure near/2 glaucoma*
#11 normal near/2 tension near/2 glaucoma*
#12 normal near/2 pressure near/2 glaucoma*
#13 pigment near/2 glaucoma*
#14 MeSH descriptor: [Exfoliation Syndrome] this term only
#15 exfoliat* near/2 syndrome*
#16 exfoliat* near/2 glaucoma*
#17 pseudoexfoliat* near/2 syndrome*
#18 pseudoexfoliat* near/2 glaucoma*
#19 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 MeSH descriptor: [Stents] explode all trees
#21 (micro-bypass* or microbypass* or micro* or bypass*) near/2 stent*
#22 bypass near/3 (trabecul* or interno)
#23 (supraciliary or suprachoroidal) near/3 (microstent* or micro stent* or implant* or drainage or device*)
#24 (Gold Micro Shunt or SOLX Gold Shunt or iStent Supra or Cypass or Aquashunt or STARflo or Esnoper)
#25 #20 or #21 or #22 or #23 or #24
#26 #19 and #25
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Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp glaucoma open angle/
14. exp intraocular pressure/
15. ocular hypertension/
16. (OAG or POAG or IOP or OHT).tw.
17. (simple$ adj3 glaucoma$).tw.
18. (open adj2 angle adj2 glaucoma$).tw.
19. (primary adj2 glaucoma$).tw.
20. (chronic adj2 glaucoma$).tw.
21. (secondary adj2 glaucoma$).tw.
22. (low adj2 tension adj2 glaucoma$).tw.
23. (low adj2 pressure adj2 glaucoma$).tw.
24. (normal adj2 tension adj2 glaucoma$).tw.
25. (normal adj2 pressure adj2 glaucoma$).tw.
26. (pigment$ adj2 glaucoma$).tw.
27. exfoliation syndrome/
28. (exfoliat$ adj2 syndrome$).tw.
29. (exfoliat$ adj2 glaucoma$).tw.
30. (pseudoexfoliat$ adj2 syndrome$).tw.
31. (pseudoexfoliat$ adj2 glaucoma$).tw.
32. or/13-31
33. exp Stents/
34. ((micro-bypass$ or microbypass$ or micro$ or bypass$) adj2 stent$).tw.
35. (bypass adj3 (trabecul$ or interno)).tw.
36. ((supraciliary or suprachoroidal) adj3 (microstent$ or micro stent$ or implant$ or drainage or device$)).tw.
37. (Gold Micro Shunt or SOLX Gold Shunt or iStent Supra or Cypass or Aquashunt or STARflo or Esnoper).tw.
38. or/33-37
39. 32 and 38
40. 12 and 39
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
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Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. open angle glaucoma/
34. intraocular pressure/
35. intraocular hypertension/
36. (OAG or POAG or IOP or OHT).tw.
37. (open adj2 angle adj2 glaucoma$).tw.
38. (primary adj2 glaucoma$).tw.
39. (chronic adj2 glaucoma$).tw.
40. (secondary adj2 glaucoma$).tw.
41. (low adj2 tension adj2 glaucoma$).tw.
42. (low adj2 pressure adj2 glaucoma$).tw.
43. (normal adj2 tension adj2 glaucoma$).tw.
44. (normal adj2 pressure adj2 glaucoma$).tw.
45. (pigment$ adj2 glaucoma$).tw.
46. exfoliation syndrome/
47. (exfoliat$ adj2 syndrome$).tw.
48. (exfoliat$ adj2 glaucoma$).tw.
49. (pseudoexfoliat$ adj2 syndrome$).tw.
50. (pseudoexfoliat$ adj2 glaucoma$).tw.
51. or/33-50
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52. Stent/
53. ((micro-bypass$ or micro$ or bypass$) adj2 stent$).tw.
54. (bypass adj3 (trabecul$ or interno)).tw.
55. ((supraciliary or suprachoroidal) adj3 (microstent$ or micro stent$ or implant$ or drainage or device$)).tw.
56. (Gold Micro Shunt or SOLX Gold Shunt or iStent Supra or Cypass or Aquashunt or STARflo or Esnoper).tw.
57. or/52-56
58. 51 and 57
59. 32 and 58
Appendix 4. ISRCTN search strategy
(Supraciliary microstent OR Suprachoroidal microstent OR Cypass OR iStent Supra OR Gold Micro Shunt OR SOLX Gold
Shunt OR Aquashunt OR STARflo OR Esnoper)
Appendix 5. ClinicalTrials.gov search strategy
(Supraciliary microstent OR Suprachoroidal microstent OR Cypass OR iStent Supra OR Gold Micro Shunt OR SOLX Gold
Shunt OR Aquashunt OR STARflo OR Esnoper)
Appendix 6. WHO ICTRP search strategy
(Supraciliary microstent OR Suprachoroidal microstent OR Cypass OR iStent Supra OR Gold Micro Shunt OR SOLX Gold
Shunt OR Aquashunt OR STARflo OR Esnoper)
Appendix 7. Data on study characteristics
Mandatory items Optional items
Methods
Study design ·Parallel group RCT i.e. people randomised
to treatment
· Within-person RCT i.e. eyes randomised
to treatment
· Cluster RCT i.e. communities randomised
to treatment
· Cross-over RCT
· Other, specify
Number of study arms
Method of randomisation
Exclusions after randomisation
Losses to follow-up
Number randomised/analysed
Method of masking
How were missing data handled? e.g. avail-
able case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes
Unit of randomisation/ unit of analysis
· One eye included in study, specify how
eye selected
· Two eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
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(Continued)
adjusted for within person correlation/both
and not adjusted for within person correla-
tion) and specify if mixture of one eye and two
eyes
· Two eyes included in study, eyes re-
ceived different treatments, specify if cor-
rect pair-matched analysis done
Participants
Country - Setting
Ethnic group
Method of recruitment
Participation rate
Equivalence of baseline characteristics (Y/
N)
Diagnostic criteria
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are reported for the people whowere
followed up only, please indicate.
Number (%) of men and women
Average age and age range
Inclusion criteria -
Exclusion criteria -
Interventions
Intervention (n = )
Comparator (n = )
· Number of people randomised to this
group
· Intervention name
· Comparator name
· Specify whether phacoemulsification, or
other intervention, performed at same time
as intervention
Comparator parameters, e.g. dosage of drugs
Outcomes
Primary and secondary outcomes as defined
in study reports
· IOP at baseline
· IOP at follow-up
·Number of glaucomamedications at base-
line
· Number of glaucoma medications at fol-
low-up
· Intraoperative complications
· Postoperative complications or secondary
surgery
· Duration of follow-up
· Loss to follow-up
· Intervals at which outcomes assessed
Adverse events reported (Y/N)
Planned/actual length of follow-up
Notes
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(Continued)
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Date of publication
Reported subgroup analyses (Y/N)
Were trial investigators contacted?Sources of funding -
Declaration of interest -
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
• Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV
research sessions from the Department of Health through the award made by the National Institute for Health Research to
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre
for Ophthalmology.
• This protocol was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the CEV UK
editorial base.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
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